Abstracts tagged "Renal"

Abstract Number: 0784 • ACR Convergence 2023
Kidney-Related Outcomes and Steroid-Sparing Effects in Patients with Active Lupus Nephritis Treated with Obinutuzumab: A Post Hoc Analysis of a Phase 2 Trial
Brad Rovin¹, Jorge Ross Terres², Sophia Giang³, Thomas Schindler⁴, Armando Turchetta⁵, Jay Garg², Richard Furie⁶, William F. Pendergraft III² and Ana Malvar⁷, ¹Ohio State University, Columbus, OH, ²Genentech, Inc., South San Francisco, CA, ³Genentech, Inc., San Francisco, CA, ⁴F. Hoffmann-La Roche Ltd, Basle, Switzerland, ⁵F. Hoffmann-La Roche Ltd, Basel, Switzerland, ⁶Northwell Health, Manhasset, NY, ⁷Hospital Fernandez, Buenos Aires, Argentina
Background/Purpose: Preservation of long-term kidney function and sustained reduction of glucocorticoid use are major therapeutic goals in lupus nephritis (LN). In the randomized, double-blind, placebo-controlled,…
Abstract Number: 1998 • ACR Convergence 2023
How to Tailor Osteoporosis Therapies in Patients with Advanced Liver Disease? Variations of Renal Function by Creatinine and Cystatin C
Cristina Rodríguez-Alvear¹, Mª Carmen López-González², Elisabet Perea-Martínez³, Antonio Avilés-Hernández³, Eduardo Garín Cascales³, Nuria Buendía Sánchez³, Irene Calabuig-Sais¹, Pilar Bernabeu-Gonzálvez³, Agustín Martínez-Sanchís¹, Joaquim Esteve-Vives³, PALOMA VELA⁴, Cayetano Miralles Maciá³, Vega Jovani⁵ and Mariano Andrés¹, ¹Dr Balmis Alicante General University Hospital-ISABIAL, Alicante, Spain, ²General University Hospital Dr. Balmis, Alacante, Spain, ³General University Hospital Dr. Balmis, Alicante, Spain, ⁴Rheumatology, Hospital General Universitario Alicante, Alicante, Spain, ⁵Department of Rheumatology, Hospital General Universitario Dr. Balmis, Alicante, Spain
Background/Purpose: Rapid bone loss and increased fractures have been described after liver transplantation. Bisphosphonates are restricted in patients with significant kidney disease, as the drugs…
Abstract Number: 0855 • ACR Convergence 2023
Real-world Experience with Avacopan in ANCA Vasculitis: A Multi-center Retrospective Cohort Analysis
Sebastian Sattui¹, Colin Diffie², Aisha Shaikh³, Julia Ford⁴, David Bulbin⁵, Ora Gewurz-Singer⁶, Faten Aqeel⁷, Reza Zonozi⁸, Abdallah Sassine Geara⁹, Dustin Le⁷, Gabriel Sauvage⁸, Madeline Chung¹⁰, Isabelle Ayoub¹⁰, Frank Cortazar¹¹, Andrew Bomback¹², Karina Guaman¹², Jason George¹³, John Niles⁸ and Duvuru Geetha⁷, ¹University of Pittsburgh, Pittsburgh, PA, ²Washington University, St. Louis, MO, ³Washington University in St. Louis, St. Louis, MO, ⁴University of Michigan, Ann Arbor, MI, ⁵Geisinger Health System, Danville, PA, ⁶University of Michigan, Huntington Woods, MI, ⁷Johns Hopkins University, Baltimore, MD, ⁸Massachusetts General Hospital, Boston, MA, ⁹University of Pennsylvania, Philadelphia, PA, ¹⁰Ohio State University, Columbus, OH, ¹¹New York Nephrology, Watervliet, NY, ¹²Columbia University, New York, NY, ¹³Geisenger Health, Danville, PA
Background/Purpose: Avacopan (AVP) is a recently approved adjunct therapy for remission induction of ANCA-associated vasculitis (AAV). Data on real-world use of AVP in AAV are…
Abstract Number: 2114 • ACR Convergence 2023
The Relationship Between Disease Activity of Rheumatoid Arthritis and Kidney Function
Sho Fukui¹, Wolfgang Winkelmayer², Sara Tedeschi¹, Javier Marrugo¹, Hongshu Guan¹, Leslie Harrold³, Heather Litman³, Tomohiro Shinozaki⁴ and Daniel Solomon⁵, ¹Brigham and Women's Hospital, Boston, MA, ²Baylor College of Medicine, Houston, TX, ³CorEvitas, LLC, Waltham, MA, ⁴Tokyo University of Science, Tokyo, Japan, ⁵Brigham and Women's Hospital, Newton, MA
Background/Purpose: Chronic kidney disease (CKD) is a common comorbidity of rheumatoid arthritis (RA) affecting 10-20% of patients. However, the influence of the longitudinal RA disease…
Abstract Number: 0857 • ACR Convergence 2023
Change in Albuminuria in Patients with ANCA-Associated Vasculitis Treated with Avacopan
Duvuru Geetha¹, Frank Cortazar², alexandre Karras³, Annette Bruchfeld⁴, Huibin Yue⁵, Peter Merkel⁶ and David Jayne⁷, ¹Johns Hopkins University, Baltimore, MD, ²New York Nephrology, Watervliet, NY, ³HEGP - APHP, Paris, France, ⁴Karolinska Institutet, Stockholm, Sweden, ⁵Amgen, Inc., Thousand Oaks, CA, ⁶University of Pennsylvania, Philadelphia, PA, ⁷University of Cambridge, Cambridge, United Kingdom
Background/Purpose: Urinary albumin:creatinine ratio (UACR) is an important biomarker of active glomerulonephritis, a common complication of antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV). In most glomerular…
Abstract Number: 2289 • ACR Convergence 2023
Short and Long Term Outcomes of Patients with Pure Membranous Lupus Nephritis Compared to Patients with Proliferative Disease
Fadi Kharouf¹, Juan Pablo Diaz Martinez², Dafna Gladman³ and Zahi Touma⁴, ¹University Health Network and University of Toronto, Toronto, ON, Canada, ²Schroeder Arthritis Institute, University Health Network, Toronto, ON, Canada, ³Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada, ⁴University of Toronto, Toronto, ON, Canada
b>Background/Purpose: Patients with pure membranous lupus nephritis (LN) are known to have a different disease course than those with proliferative disease. The aim of this…
Abstract Number: 0930 • ACR Convergence 2023
Genetic Risk Profiles of Patients with Lupus Nephritis to Identify Those at Risk for Kidney Deterioration and Eventual Damage
Aastha Khatiwada¹, bethany wolf², Isabelle Ayoub³, Juan Mejia-Vilet⁴, Ana Malvar⁵, Carl Langefeld⁶, Brad Rovin³, Jim Oates² and Betty Tsao², ¹National Jewish Health, Denver, CO, ²Medical University of South Carolina, Charleston, SC, ³Ohio State University, Columbus, OH, ⁴Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ⁵Hospital Fernandez, Buenos Aires, Argentina, ⁶Wake Forest University School of Medicine, Winston-Salem, NC
Background/Purpose: Many genetic variants are associated with lupus nephritis (LN). Yet, the majority of associated variants have a small effect size; hence, they convey small…
Abstract Number: 2336 • ACR Convergence 2023
Identification of Urine Metabolites Linked to Disease Activity That Are Modulated by Anifrolumab in a Phase 2 LN Trial Using Untargeted Metabolomics Analysis
David Jayne¹, Eduardo Mysler², Zahir Amoura³, Patrick Gavin⁴, Erik Allman⁴, Cristina Di Poto⁴, Xiang Tian⁴, Sonja Hess⁴, Eszter Csomor⁵, Philip Brohawn⁴, Daniel Muthas⁵, Adam Platt⁶, Hussein Al-Mossawi⁶, Catharina Lindholm⁵ and Nicola Ferrari⁶, ¹University of Cambridge, Cambridge, United Kingdom, ²Organizacion Medica de Investigacion, Buenos Aires, Argentina, ³French National Reference Center for SLE, Hôpital La Pitié-Salpêtrière, Paris, France, ⁴BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, ⁵BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, ⁶BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom
Background/Purpose: LN is a severe complication of SLE, affecting 21%–48% of patients.1 Development of noninvasive diagnostic tests for LN is ongoing; urinary biomarkers have good…
Abstract Number: 1112 • ACR Convergence 2023
AR882, a Potent Uricosuric Agent, Shows Favorable Uric Acid Excretion Profile Following Multiple Doses
Zancong Shen¹, Elizabeth Polvent², sarah Morris³, Rongzi Yan⁴, Shunqi Yan⁵, Robert Keenan⁶ and Li-Tain Yeh⁷, ¹Arthrosi Therapeutics, San Diego, CA, ²Arthrosi Therapeutics, Inc., Roseville, CA, ³Arthrosi Therapeutics Inc, San Diego, CA, ⁴Arthrosi Therapeutics, Inc, Irvine, CA, ⁵Arthrosi Therapeutics, Inc., Laguna Hills, CA, ⁶Arthrosi Therapeutics, Chapel Hill, NC, ⁷Arthrosi Therapeutics, Inc., Irvine, CA
Background/Purpose: The uric acid transporter inhibitor (URAT1) is responsible for the reabsorption of filtered uric acid from the renal tubular lumen. Uricosuric agents inhibit URAT1…
Abstract Number: 2378 • ACR Convergence 2023
Longitudinal Trajectories of Renal Function in ANCA-Associated Vasculitis: Findings from the Expanded Mass General Brigham Cohort
Jennifer Hanberg¹, Claire Cook¹, Xiaoqing Fu¹, Hyon K. Choi², Yuqing Zhang³ and Zachary Wallace⁴, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital and Harvard Medical School, Lexington, MA, ³Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA, ⁴Massachusetts General Hospital, Newton, MA
Background/Purpose: ANCA-associated vasculitis (AAV) commonly causes renal damage, leading to a spectrum of chronic kidney disease (CKD) and end-stage renal disease (ESRD). Quantitative descriptions of…
Abstract Number: 1116 • ACR Convergence 2023
The Current State of Sodium-Glucose Cotransporter Type 2 Inhibitor Use Among Patients with Gout at a Tertiary Academic Healthcare System
Chio Yokose¹, Baijun Zhou¹, Natalie McCormick¹, Sruthi Tanikella¹, Minna Kohler², Janeth Yinh¹, Yuqing Zhang³ and Hyon K. Choi⁴, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA, ⁴Massachusetts General Hospital and Harvard Medical School, Lexington, MA
Background/Purpose: A substantial proportion of gout patients have type 2 diabetes (T2DM), heart failure (HF), and chronic kidney disease (CKD), for which SGLT2i treatment is…
Abstract Number: 2379 • ACR Convergence 2023
A Real-World Descriptive Study of Renal Outcomes Among Patients with ANCA-Associated Vasculitis Initiating Remission Induction Therapy
Sam Oh¹, Sushmitha Inguva², Pallavi Rane² and Brian Tumminello³, ¹Amgen, Inc., South San Francisco, CA, ²Amgen, Inc., Thousand Oaks, CA, ³Amgen, Inc., San Juan Capistrano, CA
Background/Purpose: ANCA-associated vasculitis (AAV) is a group of rare autoimmune diseases characterized by inflammation and necrosis of small- to medium-sized blood vessels, commonly affecting the…
Abstract Number: 1117 • ACR Convergence 2023
Serum Urate Change Among Gout Patients Initiating Sodium-Glucose Cotransporter Type 2 Inhibitors (SGLT2i) vs. Sulfonylureas: A Comparative Effectiveness Analysis
Chio Yokose¹, Gregory Challener², Baijun Zhou², Natalie McCormick², Sruthi Tanikella², Kila Panchot², Minna Kohler³, Janeth Yinh², Yuqing Zhang⁴, David Bates⁵, James Januzzi², Meghan Sise², Deborah Wexler² and Hyon K. Choi⁶, ¹Massachusetts General Hospital, Waltham, MA, ²Massachusetts General Hospital, Boston, MA, ³Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁴Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA, ⁵Brigham and Women's Hospital, Boston, MA, ⁶Massachusetts General Hospital and Harvard Medical School, Lexington, MA
Background/Purpose: Sodium-glucose cotransporter type 2 inhibitors (SGLT2i) are currently indicated as second-line therapy for type 2 diabetes and are also approved for the treatment of…
Abstract Number: 2380 • ACR Convergence 2023
Renal Survival Rate of ANCA-associated Vasculitis in Korea: A Nationwide Population-Based Study Using Claims Data
Chan-Bum Choi¹, Jung-Min Shin², Nayeon Choi³ and Soorack Ryu³, ¹Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ²Nowon Eulji Medical Center, Eulji University School of Medicine, Seoul, South Korea, ³Biostatistical Consulting and Research Lab, Medical Research Collaborating Center, Hanyang University, Seoul, South Korea
Background/Purpose: ANCA-associated vasculitis (AAV) is a rare systemic autoimmune disease with varying reports of incidence rates and clinical manifestations. Renal involvement is one of the…
Abstract Number: 1125 • ACR Convergence 2023
A Rheumatologic Clinical Profile of the VEXAS Syndrome: Results from a Survey Conducted Among Rheumatologic Units of 126 Hospitals Across Spain
Marta López I Gómez¹, Paula García Escudero², Marta López³, Berta Magallanes López⁴, Meritxell Salles Lizarzaburu⁵, Beatriz Frade Sosa⁶, Elena Riera⁷, Ernesto Trallero Araguás⁸, MARIA ELVIRA DIEZ ALVAREZ⁹, Francisco Javier Toyos Sáenz de Miera¹⁰, Alicia Garcia Dorta¹¹, José Ángel Hernández Beriain¹², Marta Ibáñez Martínez¹³, carolina Merino¹⁴, PALOMA VELA¹⁵, Ana Victoria Orenes Vera¹⁶, Diego Dios Santos¹⁷, Jose Alberto Miranda Filloy¹⁸, Clara García Belando¹⁹, María Rodríguez Laguna²⁰, Ignacio Vázquez²¹, Joaquin Belzunegui²², Judit Font²³, Carlos de Miguel Sánchez²⁴, Zuriñe Ortiz de Zárate Caballero²⁵ and Jaime Calvo Alén²⁶, ¹Hospital Universitario de Araba, Pamplona, Spain, ²Hospital Universitario Araba, Bilbao, Spain, ³Hospital Universitario Arava, Pamplona, Spain, ⁴Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ⁵C. H. de Manresa - Fundació Althaia, Barcelona, Spain, ⁶Hospital Clínic de Barcelona, Barcelona, Spain, ⁷H. U. Mútua Terrasa, Barcelona, Spain, ⁸Department of Rheumatology, Hospital Universitario Vall d'Hebron, Barcelona, Spain, ⁹Rheumatology, Hospital Universitario de León, León, Spain, ¹⁰Hospital Virgen Macarena, Sevilla, Spain, ¹¹Rheumatology Unit, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ¹²Rheumatology, Hospital Insular de Gran Canaria, Las Palmas de Gran Canaria, Spain, ¹³C. A. U. de Salamanca, Salamanca, Spain, ¹⁴Rheumatology Department Hospital Universitario Puerta de Hierro, Majadahonda (Madrid), Spain, ¹⁵Rheumatology, Hospital General Universitario Alicante, Alicante, Spain, ¹⁶H. Arnau de Vilanova, Valencia, Spain, ¹⁷Rheumatology department, Complexo Hospitalario Universitario A Coruña (CHUAC). Instituto de Investigación Biomédica A Coruña (INIBIC), A Coruña, Spain, ¹⁸C. H. U. Lucus Augusti, Lugo, Spain, ¹⁹Hospital Los Arcos del Mar Menor, Murcia, Spain, ²⁰H. Clínico San Carlos, Madrid, Spain, ²¹H. U. Dr. Peset, Valencia, Spain, ²²H. C. Alto Deba, Donostia, Spain, ²³Hospital Universitario Germans Trias i Pujol, Badalona, Spain, ²⁴Hospital Universitario de Araba, Hematology, VItoria, Spain, ²⁵Hospital Universitario de Araba, Internal Medicine, Vitoria, Spain, ²⁶Hospital Universitario Araba, Vitoria, Spain
Background/Purpose: The newly described VEXAS syndrome is a very heterogenous disease with rheumatologic and hematologic manifestations, caused by somatic mutations affecting UBA1 gene, that still…

« Previous Page
1
…
4
5
6
7
8
…
10
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].